MRK – Merck & Co., Inc.
Merck & Company, Inc.MRK
$119.24Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $297,835,659,264.00
EPSttm : 7.29
Merck & Company, Inc.
$119.24
0.06%$0.07Float Short %
1.16
Margin Of Safety %
-18
Put/Call OI Ratio
0.67
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
4.64
Price
119.28
Target Price
123.83
Analyst Recom
1.97
Performance Q
31.11
Relative Volume
0.91
Beta
0.29
Ticker: MRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-14 | MRK | 111.01 | 0.67 | 0.50 | 705895 |
| 2026-01-15 | MRK | 110.93 | 0.67 | 0.33 | 712736 |
| 2026-01-16 | MRK | 108.85 | 0.66 | 0.60 | 728929 |
| 2026-01-20 | MRK | 109.47 | 0.60 | 0.52 | 563946 |
| 2026-01-21 | MRK | 111.09 | 0.60 | 0.34 | 570182 |
| 2026-01-22 | MRK | 109.16 | 0.60 | 0.24 | 573023 |
| 2026-01-23 | MRK | 108.17 | 0.57 | 1.17 | 597385 |
| 2026-01-26 | MRK | 107.36 | 0.59 | 0.72 | 581474 |
| 2026-01-27 | MRK | 107.85 | 0.59 | 0.97 | 585578 |
| 2026-01-28 | MRK | 106.72 | 0.59 | 0.89 | 590014 |
| 2026-01-29 | MRK | 108.33 | 0.60 | 0.56 | 597680 |
| 2026-01-30 | MRK | 110.34 | 0.60 | 0.71 | 596768 |
| 2026-02-02 | MRK | 113.37 | 0.66 | 0.60 | 544510 |
| 2026-02-04 | MRK | 118.34 | 0.66 | 0.46 | 580909 |
| 2026-02-05 | MRK | 119.75 | 0.67 | 0.44 | 586368 |
| 2026-02-06 | MRK | 121.88 | 0.66 | 0.52 | 607515 |
| 2026-02-09 | MRK | 117.56 | 0.66 | 0.95 | 581500 |
| 2026-02-10 | MRK | 117.1 | 0.67 | 0.61 | 589424 |
| 2026-02-11 | MRK | 119.28 | 0.67 | 0.36 | 593297 |
| 2026-02-12 | MRK | 119.28 | 0.67 | 0.72 | 597404 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-14 | MRK | 110.99 | 18.8 | 5098.4 | 8.97 |
| 2026-01-15 | MRK | 110.96 | 18.8 | 4447.6 | 8.97 |
| 2026-01-16 | MRK | 108.83 | 18.9 | 3969.0 | 8.97 |
| 2026-01-20 | MRK | 109.47 | 18.3 | 4608.2 | 8.97 |
| 2026-01-21 | MRK | 111.10 | 18.3 | 4841.6 | 8.97 |
| 2026-01-22 | MRK | 109.18 | 17.0 | 4017.5 | 8.97 |
| 2026-01-23 | MRK | 108.19 | 16.8 | 4674.5 | 8.97 |
| 2026-01-26 | MRK | 107.36 | 16.8 | 4712.7 | 8.97 |
| 2026-01-27 | MRK | 107.89 | 16.4 | -4399.1 | 8.97 |
| 2026-01-28 | MRK | 106.92 | 16.4 | -4637.0 | 8.97 |
| 2026-01-29 | MRK | 108.31 | 16.9 | -4252.2 | 8.97 |
| 2026-01-30 | MRK | 110.26 | 16.9 | -4173.0 | 8.97 |
| 2026-02-02 | MRK | 113.40 | 16.9 | -3989.8 | 8.97 |
| 2026-02-03 | MRK | 115.89 | 16.9 | -4094.9 | 8.97 |
| 2026-02-04 | MRK | 118.34 | -166.4 | -4410.2 | 8.97 |
| 2026-02-05 | MRK | 119.75 | -166.4 | -4573.0 | 5.25 |
| 2026-02-06 | MRK | 121.88 | -166.4 | -4474.0 | 5.25 |
| 2026-02-09 | MRK | 117.58 | -167.0 | -5557.0 | 5.13 |
| 2026-02-10 | MRK | 117.10 | -166.9 | -5034.6 | 5.15 |
| 2026-02-12 | MRK | 119.28 | -166.9 | -4960.2 | 5.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-14 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-15 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-16 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-20 | MRK | -0.63 | -1.48 | 1.31 |
| 2026-01-21 | MRK | -0.63 | -1.48 | 1.31 |
| 2026-01-22 | MRK | -0.63 | -1.48 | 0 |
| 2026-01-23 | MRK | -0.63 | -1.48 | 1.28 |
| 2026-01-26 | MRK | -0.63 | -1.54 | 1.31 |
| 2026-01-27 | MRK | -0.63 | -1.54 | 1.31 |
| 2026-01-28 | MRK | -0.63 | -1.54 | 1.36 |
| 2026-01-29 | MRK | -0.63 | -1.54 | 1.36 |
| 2026-01-30 | MRK | -0.63 | -1.54 | 1.36 |
| 2026-02-02 | MRK | -0.63 | -1.47 | 1.36 |
| 2026-02-03 | MRK | -0.57 | -1.47 | 1.36 |
| 2026-02-04 | MRK | -0.57 | -1.47 | 1.36 |
| 2026-02-05 | MRK | -0.48 | -1.47 | 1.36 |
| 2026-02-06 | MRK | -5.95 | -1.47 | 1.36 |
| 2026-02-09 | MRK | -9.43 | -1.03 | 1.36 |
| 2026-02-10 | MRK | -9.69 | -1.03 | 1.36 |
| 2026-02-11 | MRK | -9.69 | -1.03 | 1.16 |
| 2026-02-12 | MRK | -9.94 | -1.03 | 1.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-1.49
Avg. EPS Est. Next Quarter
2.12
Insider Transactions
-9.94
Institutional Transactions
-1.03
Beta
0.29
Average Sales Estimate Current Quarter
15950
Average Sales Estimate Next Quarter
16427
Fair Value
97.53
Quality Score
97
Growth Score
77
Sentiment Score
85
Actual DrawDown %
11.4
Max Drawdown 5-Year %
-43.4
Target Price
123.83
P/E
16.39
Forward P/E
12.24
PEG
2.06
P/S
4.55
P/B
5.72
P/Free Cash Flow
22.68
EPS
7.28
Average EPS Est. Cur. Y
5.15
EPS Next Y. (Est.)
9.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
28.08
Relative Volume
0.91
Return on Equity vs Sector %
8.8
Return on Equity vs Industry %
0.6
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
-1.73
EBIT Estimation
-4960.2
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees:
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading